Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationMajor depressive disorders Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Biochemical and behavioural studies have shown that citalopram is a potent inhibitor of serotonin (5-hydroxytryptamine (5HT)) uptake.”
“The elimination half-life (t1/2beta) is about 1.5 days and the systemic citalopram plasma clearance is about 0.3 to 0.4 L/minute, and total (oral) plasma clearance is about 0.4 L/minute.”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“The metabolism of citalopram is only partly dependent on the hepatic cytochrome P450 isozyme CYP2D6 and, unlike some other SSRIs, citalopram is only a weak inhibitor of this important enzyme system which is involved in the metabolism of many drugs (including antiarrhythmics, neuroleptics, beta-blockers, tricyclic antidepressants and some SSRIs).”